Literature DB >> 1607254

Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney. A Southwest Oncology Group study.

S A Taylor1, P Goodman, E D Crawford, W J Stuckey, R L Stephens, E R Gaynor.   

Abstract

The Southwest Oncology Group studied the response rate and toxicity of didemnin B (3.47 mg/m2 i.v. q 28 days) in patients with advanced renal cell carcinoma. There were no responses in 22 response evaluable patients. Toxicity was significant with 10 patients having grade 3 or 4 toxicity. Toxicity seen included nausea and vomiting, exacerbation of coronary artery disease, hyperglycemia, anorexia, diarrhea and hepatitis. Didemnin B was toxic but inactive in patients with renal cell treated at this dose.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1607254     DOI： 10.1007/bf01275484

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  2 in total

1.  Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide.

Authors:  F A Dorr; J G Kuhn; J Phillips; D D von Hoff
Journal:  Eur J Cancer Clin Oncol       Date:  1988-11

2.  Didemnins: antiviral and antitumor depsipeptides from a caribbean tunicate.

Authors:  K L Rinehart; J B Gloer; R G Hughes; H E Renis; J P McGovren; E B Swynenberg; D A Stringfellow; S L Kuentzel; L H Li
Journal:  Science       Date:  1981-05-22       Impact factor: 47.728
  2 in total
  5 in total

1.  Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319).

Authors:  A Mittelman; H G Chun; C Puccio; N Coombe; T Lansen; T Ahmed
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  Phase II study of low dose cyclophosphamide and intravenous interleukin-2 in metastatic renal cancer.

Authors:  W D Quan; G E Dean; G Lieskovsky; M S Mitchell; R A Kempf
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

Review 3.  Phase II clinical trial of didemnin B in previously treated small cell lung cancer.

Authors:  D M Shin; P Y Holoye; A Forman; R Winn; R Perez-Soler; S Dakhil; J Rosenthal; M N Raber; W K Hong
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

4.  Isolation and characterization of marine Brevibacillus sp. S-1 collected from South China Sea and a novel antitumor peptide produced by the strain.

Authors:  Lanhong Zheng; Yao Yi; Jia Liu; Xiukun Lin; Kangli Yang; Mei Lv; Xinwen Zhou; Jianhua Hao; Junzhong Liu; Yuan Zheng; Mi Sun
Journal:  PLoS One       Date:  2014-11-05       Impact factor: 3.240

5.  Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis.

Authors:  Andrea Perne; Markus K Muellner; Magdalena Steinrueck; Nils Craig-Mueller; Julia Mayerhofer; Ilse Schwarzinger; Mathew Sloane; Iris Z Uras; Gregor Hoermann; Sebastian M B Nijman; Matthias Mayerhofer
Journal:  PLoS One       Date:  2009-12-16       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.